Key facts
- AstraZeneca has been exploring a potential merger with U.S. rival Bristol Myers Squibb.
- The combined entity could be valued at approximately $400 billion.
- The companies have held talks in recent months.
- A deal could be finalized soon, delayed, or abandoned.
UK-based pharmaceutical giant AstraZeneca has reportedly been in discussions regarding a potential merger with its U.S. counterpart, Bristol Myers Squibb. The Financial Times, citing sources familiar with the matter, reported that the companies have held talks in recent months about a tie-up that could create a combined entity valued at nearly $400 billion.
A deal could be finalized soon, but the report cautioned that it might also face delays or ultimately fail. AstraZeneca declined to comment on the report, while Bristol Myers Squibb did not immediately respond to a request for comment.
This potential megadeal comes approximately a dozen years after AstraZeneca successfully fended off a takeover bid from Pfizer. AstraZeneca's share price has seen significant growth under CEO Pascal Soriot's 14-year leadership, outperforming the FTSE 100 index and rival GSK. Recent financial results indicate continued strong demand for its cancer and rare disease treatments, which are projected to account for a substantial portion of future sales.